Newsroom

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (siège social : Tokyo, président-directeur général : Toshiaki Nagasato) a annoncé aujourd'hui que le morcamilast (nom international non propriétaire proposé ; code de développement : ME3183), un inhibiteur sélectif de la phosphodiestérase-4 (PDE4), a obtenu la désignation de médicament orphelin par la Commission européenne (CE) pour le traitement de la pustulose palmo-plantaire (PPP). La pustulose palmo-plantaire est une maladie inflammatoire...

NEUCHÂTEL, Switzerland--(BUSINESS WIRE)--Unlike traditional EDOF lenses, Lucidis® delivers full-range visual performance comparable to a premium trifocal IOL without disturbances....

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Hauptsitz: Tokio, President und Representative Director: Toshiaki Nagasato) gab heute bekannt, dass Morcamilast (vorgeschlagener internationaler nicht-proprietärer Name; Entwicklungscode: ME3183), ein selektiver Phosphodiesterase-4 (PDE4)-Inhibitor, von der Europäischen Kommission den Status als Arzneimittel für seltene Leiden (Orphan-Arzneimittel) zur Behandlung von Palmoplantarer Pustulose (PPP) erhalten hat. Palmoplantare Pustulose ist ei...

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (hoofdzetel: Tokio, voorzitter en vertegenwoordigend directeur: Toshiaki Nagasato) maakte vandaag bekend dat morcamilast (voorgestelde algemene internationale benaming (international nonproprietary name - INN); ontwikkelingscode: ME3183), een selectieve PDE4-remmer (fosfodiësterase-4), van de Europese Commissie (EC) de aanwijzing als weesgeneesmiddel heeft verkregen voor de behandeling van pustulosis palmoplantaris (PPP). Pustulosis palmoplan...

BARCELONA, Spain--(BUSINESS WIRE)--Arrcus, the leader in distributed networking infrastructure today announced and Lightstorm, Asia-Pacific's leading digital infrastructure and connectivity provider, today announced a strategic partnership to deliver purpose-built networking solutions for distributed AI inference and training workloads. Designed for AI cloud providers, enterprises, and infrastructure operators, the partnership combines Arrcus' intelligent routing capabilities with Lightstorm's...

ZURICH, Switzerland--(BUSINESS WIRE)--On Announces Fourth Quarter and Full Year Results, and the Filing of its Annual Report on Form 20-F for 2025...

SAN FRANCISCO--(BUSINESS WIRE)--RecovryAI today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its Virtual Care Assistants (VCAs), physician-prescribed, patient-facing clinical AI designed to support patients during post-operative recovery. The designation, reserved for medical devices that address serious conditions and demonstrate the potential to meaningfully improve existing standards of care, enables earlier and more frequent engag...

SUNNYVALE, Calif.--(BUSINESS WIRE)--Proofpoint, Inc., a leading cybersecurity and compliance company, today announced the global availability of Nuclei Discovery & Archive Suite, a new digital communications governance and archiving (DCGA) solution purpose-built for modern small- to medium-sized (SMB) organizations. Designed to address the growing regulatory, e-discovery, and operational challenges facing lean IT and compliance teams, the Nuclei Suite combines rapid deployment, powerful ent...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION   (a) Full name of discloser: Massachusetts Financial Services Company (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficia...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: River Global Investors LLP 213800HIGHFCAY9K8Z97 (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and bene...